Intratect (Human Normal Immunoglobulin)

Human normal immunoglobulin provides passive immunity by delivering a broad spectrum of IgG antibodies derived from pooled plasma donors. These antibodies bind to pathogens, neutralize toxins, promote opsonization, and modulate immune cell activity through Fc receptor interactions, thereby enhancing the recipient’s ability to fight infections and regulate abnormal immune responses.

The dosing regimen for Intratect is individualized and determined by the prescribing healthcare professional based on the patient’s weight, clinical condition, and therapeutic goals. Doses are typically calculated in grams of IgG per kilogram of body weight and administered intravenously under medical supervision.

Safety data for Intratect in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Use during pregnancy or while breastfeeding should be considered only if the potential benefits outweigh any potential risks, and decisions should be made by the treating physician.

To place an order for Intratect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Intratect is a pooled human normal immunoglobulin similar in composition to other intravenous immunoglobulin (IVIG) preparations. Differences among products may include manufacturing processes, stabilizers, and concentration, which can affect infusion rates, tolerability, and storage requirements. Clinicians select a specific IVIG based on patient tolerance, product availability, and institutional experience.

Intratect must be stored refrigerated at 2–8 °C (36–46 °F). It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and may be gently mixed if required, following the manufacturer’s instructions.

Intratect is administered intravenously by a healthcare professional, typically as an infusion over several hours. The infusion rate is adjusted based on patient tolerance, and vital signs are monitored throughout the procedure. Premedication with antihistamines or analgesics may be used to reduce infusion‑related reactions, according to clinical guidelines.

Serious adverse reactions to Intratect can include anaphylaxis, aseptic meningitis, hemolytic anemia, thromboembolic events, and renal dysfunction. Patients should be observed closely during and after infusion for signs of these events, and immediate medical intervention should be initiated if severe reactions occur.

Intratect is contraindicated in patients with known severe IgA deficiency who have anti‑IgA antibodies, as they are at increased risk for anaphylactic reactions. Additionally, individuals with a history of severe hypersensitivity to immunoglobulin products or any of the excipients should avoid its use. Clinical assessment is required before initiating therapy.